1. Home
  2. LSAK vs PRTA Comparison

LSAK vs PRTA Comparison

Compare LSAK & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSAK
  • PRTA
  • Stock Information
  • Founded
  • LSAK 1997
  • PRTA 2012
  • Country
  • LSAK South Africa
  • PRTA Ireland
  • Employees
  • LSAK N/A
  • PRTA N/A
  • Industry
  • LSAK Investment Bankers/Brokers/Service
  • PRTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • LSAK Finance
  • PRTA Health Care
  • Exchange
  • LSAK Nasdaq
  • PRTA Nasdaq
  • Market Cap
  • LSAK 344.5M
  • PRTA 346.4M
  • IPO Year
  • LSAK N/A
  • PRTA N/A
  • Fundamental
  • Price
  • LSAK $4.53
  • PRTA $6.29
  • Analyst Decision
  • LSAK
  • PRTA Buy
  • Analyst Count
  • LSAK 0
  • PRTA 9
  • Target Price
  • LSAK N/A
  • PRTA $27.67
  • AVG Volume (30 Days)
  • LSAK 29.0K
  • PRTA 1.3M
  • Earning Date
  • LSAK 09-03-2025
  • PRTA 08-07-2025
  • Dividend Yield
  • LSAK N/A
  • PRTA N/A
  • EPS Growth
  • LSAK N/A
  • PRTA N/A
  • EPS
  • LSAK N/A
  • PRTA N/A
  • Revenue
  • LSAK $574,080,000.00
  • PRTA $137,935,000.00
  • Revenue This Year
  • LSAK $1.06
  • PRTA N/A
  • Revenue Next Year
  • LSAK $13.32
  • PRTA $122.02
  • P/E Ratio
  • LSAK N/A
  • PRTA N/A
  • Revenue Growth
  • LSAK 4.13
  • PRTA 54.55
  • 52 Week Low
  • LSAK $3.39
  • PRTA $4.32
  • 52 Week High
  • LSAK $5.60
  • PRTA $25.42
  • Technical
  • Relative Strength Index (RSI)
  • LSAK 52.46
  • PRTA 56.80
  • Support Level
  • LSAK $4.45
  • PRTA $6.16
  • Resistance Level
  • LSAK $4.70
  • PRTA $6.60
  • Average True Range (ATR)
  • LSAK 0.19
  • PRTA 0.27
  • MACD
  • LSAK -0.01
  • PRTA 0.04
  • Stochastic Oscillator
  • LSAK 45.65
  • PRTA 67.90

About LSAK Lesaka Technologies Inc.

Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates two reportable segments: Merchant and Consumer. The company operates mainly within South Africa. The Merchant segment that derives majority revenue includes activities related to the provision of goods and services provided to corporate and other juristic entities. It earns fees from processing activities performed for its customers and revenue generated from the distribution of prepaid airtime. The Consumer segment includes activities related to the provision of financial services to customers, including bank accounts, loans, and insurance products. The firm charges monthly administration fees for all bank accounts.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: